Resources
BsAb: Engineered antibody binding two antigens, activating immune cells, inhibiting tumor signaling. Market: $5.8B in 2023, expecting multi-billion growth by 2030.
Cullinan made an initial payment of $25 million and committed up to $600 million in milestone payments, along with a potential royalty of nearly 20% on sales.
Innopedia is a robust database designed to provide researchers with enhanced research tools and data support. The database offers browsing, searching, and analytical capabilities for tumor cell lines, engineered cell lines, and standard antibodies.
Kinases regulate nearly all aspects of cellular activities, and alterations in their expression or gene mutations can lead to the development of cancer and other diseases.
Antibodies, CAR-T cells, and other biopharmaceuticals rely on the specificity of their target binding, which is a critical factor in assessing the quality of these drugs.
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
K-ras was the first identified oncogene in the cellular genome, KRAS protein can bind GDP/GTP and possess intrinsic
Membrane Proteins Screening Array-AB5000
Antibodies, CAR-T cells, and other biopharmaceuticals rely on the specificity of their target binding, which is a critical factor in assessing the quality of these drugs.
Ba/F3 Kinase Cell Lines
Kinases regulate nearly all aspects of cellular activities, and alterations in their expression or gene mutations can lead to the development of cancer and other diseases.
Heavy Chain Antibody
Nanobodies, primarily derived from camelid animals, have become a hotspot in antibody-drug development, owing to their small molecular weight and ease of modification. We have developed the KY-HC-mouse, a naturally light-chain deficient mouse that produces solely heavy-chain antibodies.
Common Light Chain Antibody
Bi-specific antibody (BsAb) is an attractive therapeutic antibody format for treating different diseases. The matching of light chains is the central issue of BsAb manufacturing. Here we developed a Common Light Chain mouse named KY-CLC-mouse. KY-CLC-mouse has no λ light chain expression with an identical κ light chain. The mouse was validated by developing different monoclonal antibodies against various antigens with an identical light chain and high affinity.
Innopedia Database
Innopedia is a robust database designed to provide researchers with enhanced research tools and data support. The database offers browsing, searching, and analytical capabilities for tumor cell lines, engineered cell lines, and standard antibodies.
